Megan R Haymart1,2, Mousumi Banerjee2,3, David Reyes-Gastelum1,2, Elaine Caoili4, Edward C Norton2,5,6. 1. Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan. 2. Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan. 3. Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan. 4. Department of Radiology, University of Michigan, Ann Arbor, Michigan. 5. Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor, Michigan. 6. Department of Economics, University of Michigan, Ann Arbor, Michigan.
Abstract
Context: Thyroid cancer incidence increased with the greatest change in adults aged ≥65 years. Objective: To determine the relationship between area-level use of imaging and thyroid cancer incidence over time. Design, Setting and Participants: Longitudinal imaging patterns in Medicare patients aged ≥65 years residing in Surveillance, Epidemiology, and End Results (SEER) regions were assessed in relationship to differentiated thyroid cancer diagnosis in patients aged ≥65 years included in SEER-Medicare. Linear mixed-effects modeling was used to determine factors associated with thyroid cancer incidence over time. Multivariable logistic regression was used to determine patient characteristics associated with receipt of thyroid ultrasound as initial imaging. Main Outcome Measure: Thyroid cancer incidence. Results: Between 2002 and 2013, thyroid ultrasound use as initial imaging increased (P < 0.001). Controlling for time and demographics, use of thyroid ultrasound was associated with thyroid cancer incidence (P < 0.001). Findings persisted when cohort was restricted to papillary thyroid cancer (P < 0.001), localized papillary thyroid cancer (P = 0.004), and localized papillary thyroid cancer with tumor size ≤1 cm (P = 0.01). Based on our model, from 2003 to 2013, at least 6594 patients aged ≥65 years were diagnosed with thyroid cancer in the United States due to increased use of thyroid ultrasound. Thyroid ultrasound as initial imaging was associated with female sex and comorbidities. Conclusion: Greater thyroid ultrasound use led to increased diagnosis of low-risk thyroid cancer, emphasizing the need to reduce harms through reduction in inappropriate ultrasound use and adoption of nodule risk stratification tools.
Context:Thyroid cancer incidence increased with the greatest change in adults aged ≥65 years. Objective: To determine the relationship between area-level use of imaging and thyroid cancer incidence over time. Design, Setting and Participants: Longitudinal imaging patterns in Medicare patients aged ≥65 years residing in Surveillance, Epidemiology, and End Results (SEER) regions were assessed in relationship to differentiated thyroid cancer diagnosis in patients aged ≥65 years included in SEER-Medicare. Linear mixed-effects modeling was used to determine factors associated with thyroid cancer incidence over time. Multivariable logistic regression was used to determine patient characteristics associated with receipt of thyroid ultrasound as initial imaging. Main Outcome Measure: Thyroid cancer incidence. Results: Between 2002 and 2013, thyroid ultrasound use as initial imaging increased (P < 0.001). Controlling for time and demographics, use of thyroid ultrasound was associated with thyroid cancer incidence (P < 0.001). Findings persisted when cohort was restricted to papillary thyroid cancer (P < 0.001), localized papillary thyroid cancer (P = 0.004), and localized papillary thyroid cancer with tumor size ≤1 cm (P = 0.01). Based on our model, from 2003 to 2013, at least 6594 patients aged ≥65 years were diagnosed with thyroid cancer in the United States due to increased use of thyroid ultrasound. Thyroid ultrasound as initial imaging was associated with female sex and comorbidities. Conclusion: Greater thyroid ultrasound use led to increased diagnosis of low-risk thyroid cancer, emphasizing the need to reduce harms through reduction in inappropriate ultrasound use and adoption of nodule risk stratification tools.
Authors: R Michael Tuttle; Rebecca Leboeuf; Richard J Robbins; Rebecca Qualey; Keith Pentlow; Steven M Larson; Chee Y Chan Journal: J Nucl Med Date: 2006-10 Impact factor: 10.057
Authors: Salvatore Vaccarella; Silvia Franceschi; Freddie Bray; Christopher P Wild; Martyn Plummer; Luigino Dal Maso Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Mousumi Banerjee; Daniel G Muenz; Joanne T Chang; Maria Papaleontiou; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2014-07-17 Impact factor: 5.958
Authors: C T Sawin; A Geller; P A Wolf; A J Belanger; E Baker; P Bacharach; P W Wilson; E J Benjamin; R B D'Agostino Journal: N Engl J Med Date: 1994-11-10 Impact factor: 91.245
Authors: Kirsten Bibbins-Domingo; David C Grossman; Susan J Curry; Michael J Barry; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Albert L Siu; Chien-Wen Tseng Journal: JAMA Date: 2017-05-09 Impact factor: 56.272
Authors: Debbie W Chen; David Reyes-Gastelum; Archana Radhakrishnan; Ann S Hamilton; Kevin C Ward; Megan R Haymart Journal: JAMA Surg Date: 2020-10-01 Impact factor: 14.766
Authors: Nazanene H Esfandiari; David T Hughes; David Reyes-Gastelum; Kevin C Ward; Ann S Hamilton; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2019-12-01 Impact factor: 5.958
Authors: Colin Davenport; Jack Alderson; Ivan G Yu; Aoiffe C Magner; Diarmuid M O'Brien; Meabh Ni Ghiollagain; Sinead Kileen; Mark Heneghan; Muna Sabah; Eamon Leen; John H McDermott; Seamus Sreenan; Neil Hickey; Tommy Kyaw-Tun Journal: Endocrine Date: 2019-04-06 Impact factor: 3.633
Authors: L Dal Maso; C Panato; A De Paoli; V Mattioli; D Serraino; R Elisei; G Zoppini; C Gobitti; E Borsatti; E Di Felice; F Falcini; S Ferretti; S Francisci; P Giorgi Rossi; S Guzzinati; G Mazzoleni; D Pierannunzio; S Piffer; S Vaccarella; M Vicentini; M Zorzi; S Franceschi; U Fedeli Journal: J Endocrinol Invest Date: 2021-01-18 Impact factor: 4.256